INTRODUCTION
Allergy does not follow a classical Mendelian inheritance pattern, typical of monogenic disorders, but a multifactorial pattern, involving interactions between different genetic and environmental factors [1] . Genome-Wide Association Studies (GWASs) performed in the field of allergy have indicated that a large number of genes can influence the disease [2] . Among them, PTGDR, a prostaglandin D2 receptor, has been proposed among asthma (including allergic asthma) candidate genes [3, 4] . Prostaglandin D2 (PGD2) is increased after exposure to allergens [5] . The production of PGD2 has been linked to allergic asthma, atopic dermatitis and allergic rhinitis and conjunctivitis, and PGD2 has been detected in skin, tears and nasal secretion of allergic patients [6] .
Locally, PGD2 acts through two transmembrane receptors, PTGDR (Prostaglandin D2
Receptor or DP1) and CRTH2 (chemokine receptor-homologous molecule expressed on Th2 lymphocytes or DP2), belonging to the superfamily of heterotrimeric G proteincoupled receptors [7] .
Regarding PTGDR, linkage studies found a region located on chromosome 14 as a candidate to host genetic markers linked to asthma or related phenotypes [8, 9] .
Association studies revealed an association between PTGDR and allergic diseases [2, 3, 10, 11] . Nevertheless, replication of association studies of PTGDR has generated some controversy, related to ethnicity and other factors. Thus, Single Nucleotide Polymorphisms (SNPs) of PTGDR have been associated with asthma in Caucasian populations [3, 4] and in an African American population [4] , but not in Australian [12] , Mexican, Puerto Rican, another African-American [13] and China-Han populations [14] .
In addition, chronic rhinosinusitis with nasal polyposis has been associated with J Investig Allergol Clin Immunol 2020; Vol. 30 (2) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0411 different prostaglandin receptors, including PTGDR, and also with the prostaglandin D2 synthase (PTGDS) [15] . Despite ethnic differences, PTGDR is one of the genes whose association with asthma and atopic asthma has been replicated [16] , specifically in the case of polymorphisms of the promoter region, such as -549C/T, -441C/T and -197C/T [3, 4, 10] . These polymorphisms are located in binding sites of transcription factors, which could modify transcription levels [4] . Some haplotypic combinations of these variants have been associated with an increased transcriptional activity of PTGDR [3, 4, 10, 11] .
In this study we decided to investigate the role of PTGDR in allergic diseases, including allergic asthma. The objectives of this study were: Firstly, to determine the PTGDR expression levels in allergic patients compared to controls; secondly, to compare allelic, genotypic and haplotypic frequencies of 9 PTGDR promoter polymorphisms in these two populations; lastly, to examine the putative relationship between PTGDR expression levels and the presence of PTGDR promoter polymorphisms.
METHODS

Study population
For this observational, analytical, case-control study of 314 Caucasian individuals (age > 16 yr), potentially eligible were selected over a period of 4 years, with 307 finally included. Seven samples were excluded because they did not fulfill the quality criteria for molecular analysis. The statistical power of the sample size was analyzed. informed written consent from study subjects was obtained. One hundred and twelve individuals were enrolled as controls, provided they met the following criteria: (i) no symptoms or history of asthma or other pulmonary diseases; (ii) no symptoms or history of rhinitis; (iii) no symptoms or history of allergic diseases; (iv) negative skin prick tests to a battery of common aeroallergens; (v) absence of family history of asthma, rhinitis or atopy. In addition, 195 patients were recruited if they met these criteria: (i) physician-diagnosis of respiratory allergy (allergic asthma and/or allergic rhinitis); (ii) at least one positive skin prick test to a battery of previously described common aeroallergens [3] . A patient was considered to have allergic asthma if he/she had asthmatic symptoms restated to the exposure to the aeroallergens he/she was sensitized to and a positive bronchodilator or methacholine test. Allergic rhinitis was diagnosed with symptoms suggesting allergic rhinitis were present and correlated to patient's sensitizations. Skin prick tests were performed following the European Academy of Allergy and Clinical Immunology (EAACI) allergen standardization and skin test subcommittee recommendations [17] . Skin tests were considered positive if there were at least one wheal reaction of >3mm of diameter greater than the negative control. Patients should have positive skin prick test to at least one allergen.
Concerning skin tests, patients were considered monosensitized if they had positive skin prick test to only one group of aeroallergens (house dust mites, molds, pollens or epithelia) and polysensitized if they had positive skin tests to two or more groups. 
Genotype analysis
DNA extraction from total blood was performed using the automated system MagNA Pure Compact (Roche Applied Science, USA). A 1416 bp fragment comprising the nine single nucleotide polymorphism (SNP) positions -1289G>A, -1122T>C, -881C>T, -834C>T, -613C>T, -549T>C, -441C>T, -197T>C and -95G>T of the PTGDR promoter region was amplified by polymerase chain reaction. Forward and reverse primers employed in these amplifications were 5´ GGCATGAGGCCTAAAAATGAG 3´ and 5´ GAAGAAGGCGAAGGCTTGG 3´, respectively. Reaction mixtures and cycling conditions were performed as previously described [10] . To purify amplified fragments, ExoSAP-IT (USB, Cleveland, USA) was used. Amplicons were sequenced in an ABI PRISM 377 DNA Sequencer (Thermo Fisher Scientific, Waltham, USA). Chromas 2.3 (Technelysium, Tewantin, Australia) were employed for the analysis. Specific quality measures were taken in all procedures following EMQN guidelines [18] .
RNA Extraction and cDNA Preparation
Total RNA was isolated from peripheral blood with RiboPure-Blood kit (Thermo Fisher Scientific, Waltham, USA). DNase treatment was performed using Turbo DNAse 
Selection of constitutive expression genes
Real-time Quantitative PCR
Expression analyses of the 3 genes were performed in a LightCycler 480 system (Roche Applied System, Manheim, Germany). Each well contained a final PCR reaction volume of 15 µL: 7.5µl Master Mix SYBR Green I (2X) (Roche Applied Science, Indianapolis, USA), 600 nM of each forward and reverse primer and 25 ng of cDNA template. PCR conditions included 10 min at 95ºC followed by 45 cycles of 10 s at 95ºC for denaturation, 10 s at 60ºC for annealing and 10 s at 72ºC for polymerization. Finally, melting curve analyses were conducted to check the specificity of the qPCR obtained products. All reactions were performed in triplicate and in each experiment nontemplate controls were included to detect any contamination. In order to detect and correct any potential inter-assay variations a known concentration sample (calibrator) was included. Control and patient samples were included in each experiment. The threshold cycle (Ct) was automatically determined using the LightCycler 480 Software.
PTGDR expression levels were normalized to GAPDH and TBP mRNA levels using the Analyses of allelic and genotypic distributions, as well as a study of haplotype distribution and the Hardy-Weinberg equilibrium were performed using the Shesis on
. Correction for multiple comparisons, false-positive report probability (FPRP), and statistic power were also calculated as statistic control.
Statistical analyses were performed by using SPSS 17.0 software (IBM, Chicago, USA).
ROC analysis was applied for sensitivity and specificity study.
RESULTS
Characteristics of the study population
Phenotypic characteristics of the study population are shown in Table 1 . Briefly, age was significantly lower in patients than in controls (p-value<0.001) and total IgE levels were significantly lower in controls (p-value<0.001). In addition, patients diagnosed with both allergic asthma and allergic rhinitis had significantly higher IgE levels than patients suffering only from rhinitis (p-value= 0.013).
Asthma severity was evaluated according to GINA guidelines [25] . Intermittent asthma was the most common (48%), followed by moderate persistent asthma (32%). Rhinitis classification was made following ARIA guidelines modified by Valero and cols [26] , being moderate persistent rhinitis (41%) and moderate intermittent rhinitis (22%) the more frequent types. The most common aeroallergen sensitization was to pollen (146 patients), followed by mites (139 patients).
Selection of Reference Genes
A general recommendation in gene expression studies is to choose reference genes with a similar expression level to the target gene [27] . According to this and due to its lowest variability among all analyzed genes, TBP was the selected reference gene (see Table 1 of Supplementary material). Following MIQE guidelines two housekeeping genes should be included. In this sense, GAPDH was also included because it has been broadly used in gene expression studies of asthma [28, 29] . Before evaluating expression data, correlation of the two selected reference genes was confirmed (Spearman´s rho of 0.783, p<0.001).
Expression Analysis
PTGDR expression levels were significantly higher in the population of allergic patients than in controls (p < 0.001). This highly statistical difference was also observed in all subgroups of allergic patients. No significant differences in PTGDR gene expression levels were observed between the different subgroups of allergic patients, although PTGDR expression levels were slightly higher in patients sensitized to pollens (see Table 2 ). We have considered possible influences of anti-inflammatory medications in the expression of PTGDR. No patient was taking NSAID or oral corticosteroids at blood sampling. In addition, 32 patients were receiving allergen immunotherapy (AIT) and 19 more patients had previously received AIT. No statistically significant differences (p=0.436) in the expression levels of PTGDR of patients receiving AIT respect to patients not receiving AIT were found. Concerning pollen allergy, the sample was obtained during the pollen season in a total of 58 patients out of 152. Again, no statistically significant differences were observed when the sample was obtained during the pollen season or out of it (p=0.624). This also implies that medication used to treat pollen allergy, in particular nasal and/or inhaled corticosteroids have no effect in the expression of PTGDR. In addition, the bioavailability of inhaled corticosteroid, which are administered at higher doses that nasal corticosteroids, is very low of even negligible for some of them [30] . The exposition to the rest of aeroallergens was not seasonal.
PTGDR expression levels as a potential biomarker of allergy sensitization
We compared PTGDR mRNA expression levels with serum IgE levels as allergy biomarkers. A ROC curve was performed, obtaining an area under the curve of 0.654, 95% CI (0.588-0.721) providing a cut off for the PTGDR expression of 0.509, results are shown in Table 3 .
Total IgE levels significantly increased according to the number of sensitization groups; however, these differences were not observed for PTGDR expression levels (see Table   4 ). 
Genetic Association Analysis
In the association study of the 9 PTGDR promoter polymorphisms, statistically significant differences between allergic patients and controls were observed for the allelic and the genotypic frequencies of -1289G>A and -1122T>C SNPs. As it happened with the PTGDR gene expression, the differences in the genotype distribution of these SNPs between allergic patients and controls were also observed for the subphenotypes of Atopic Asthma and Atopic Rhinitis. When the type of allergic sensitization was taken into account, significant differences were observed in patients with allergy to pollens (p=0.028). Also, in the group of patients sensitized to mites and pollens, statistically significant differences were found for the -1289G>A and -1122T>C polymorphisms Table 5 ). No statistically significant differences were observed for the rest of the SNPs between patient and controls populations (see Table 5 ), nor for the general haplotype distribution (see Table 6 ).
Association between PTGDR promoter polymorphisms and expression levels
In the total population of patients and controls, the mutant homozygous genotypes AA and CC of polymorphisms -1289G>A and -1122T>C respectively, were both associated to statistically significantly lower PTGDR expression levels, p=0.034 (see Table 7 ). These differences were especially confirmed in the subgroup of patients simultaneously sensitized to pollen and mites, where genotypes carrying the mutant alleles are associated with significant lower PTGDR expression, p=0.009. Interestingly these mutant alleles associated to lower PTGDR levels were significantly more frequent in controls than in any of the allergic groups (see Table 7 ).
DISCUSSION
In the present study, highly significant differences in PTGDR expression levels between controls and allergic patients were observed. Thus, allergic patients showed increased PTGDR expression levels respect to non-allergic subjects. PTGDR expression levels were independent of the aeroallergen group sensitization and/or clinical manifestations, although expression levels were slightly higher in patients sensitized to
pollens. This suggests that expression levels of PTGDR could be a general trait of atopy.
In this sense, arachidonic acid derivatives such prostaglandins and leukotrienes are important mediators in allergic reactions and are responsible of great part of symptoms of rhinitis and asthma. Thus, PGD2 is the most abundantly produced cyclooxygenase metabolite of arachidonic acid in response to environmental allergens and has been proposed as a mast cell activation marker [31] . PGD2 produces bronchoconstriction, vasodilation, increasing of capillary permeability and mucus production in allergic patients [32] . these considerations should be followed in order to provide reliable results. In this sense, we carefully followed all MIQE recommendations and performed a previous deep analysis in order to select the most appropriate constitutive genes from 19
candidates. In this study, the expression of PTGDR is able to clearly differentiate between allergic patients and controls with robustness. In addition, it can be detected by a simple and rapid technique from an easy to obtain biological sample and has a better sensitivity that IgE levels. However, the scarce specificity and NPV make limit its potential for differential diagnosis. We found that total IgE levels increased according to the number of groups of sensitization [33] . This is not the case for PTGDR levels, which did not exhibit significant differences regarding the number of sensitization groups. These results may indicate that PTGDR could be a good indicator of the inflammation activation mechanism of allergy rather than of severity. In addition, our results show that PTGDR expression determination could be consider as a complementary diagnostic test when it is suspected that IgE determination was not sensitive enough. With regard to the genotyping analysis, we found that the mutant alleles of -1289G>A and -1122T>C SNPs were significantly more frequent in controls than in any of the groups of allergic patients. In addition, these mutant alleles were associated to lower levels of PTGDR expression suggesting that the presence of these SNPs could be associated with a decreased risk to develop the disease. Both SNP are in linkage disequilibrium suggesting that the analysis of only one of them could be informative enough. African Americans, and the -441T>C variant in a Caucasian population [4] . In a Spanish population, the SNP -197T>C was associated with asthma, particularly allergic asthma [11] . In another study, the SNP -613C>T was associated with allergy, mainly with cosensitization to mites and pollens, whereas the SNP -549T>C was close to significance (p = 0.09) in patients sensitized to both pollen and mites [11] . However, studies in Mexican, Puerto Rican and African American populations showed no involvement of SNP -549T>C, -441T>C and -197T> C [13] in the development of asthma, as well as studies on an Australian population [12] . These discrepancies may be due to small ethnic differences between populations or to environmental factors, since only in Caucasian population these polymorphisms were associated with asthma. In our work we have not found any significant association for these SNPs, but it should be taken into account that that our work focuses on allergic patients and not on asthma. Most of these studies lack of functional analysis. In our study, the expression analysis suggests that the association of both -1289G>A and -1122T>C SNPs could be related to their transcriptional role. We emphasized that expression analysis can contribute to identify the mechanisms underlying the inflammatory pathways related to allergic disease and to check the functional role of SNPs suggested in association studies. We have shown that PTGDR gene expression seems to be determined in part by the presence of the -1289G>A and -1122T>C SNPs. However, it was also observed, that for the same genotype the expression levels still having some differences between controls and allergic patients, which indicate that additional factors such as other SNPs and/or epigenetic factors also seem to be acting over PTGDR expression. Potential limitations of this study could be initially related to the sample size that was solved by analyzing the statistical power. Distribution of sex between patient and control groups was solved by logistic regression. The probability of a type 1 error was solved by applying the Bonferroni correction and the False Positive Report Probability.
Finally, the putative selection of an inappropriate constitutive gene was solved by analyzing 19 genes in both control and patients.
This study opens interesting insights on PTGDR as a potential predictor marker of allergy, which could deeper explain how it is involved in the disease and its consequences on the activation of the inflammation pathway. In addition, this could contribute to the analysis of PTGD receptors as therapeutic targets highlighting the potential role of genetic variants that impaired the expression of PTGD receptors, as possible pharmacogenetic predictors of therapeutic response to their antagonists [34] .
Further studies including validation of these results in different populations would be of great interest to determine the specific mechanisms by which the increased expression of PTGDR is related to the occurrence of allergic phenotype and can impact on therapeutic strategies.
CONCLUSIONS
PTGDR expression levels were associated with allergy. The -1289G>A and -1122T>C
promoter SNPs are candidates to explain some of the variation in the expression levels observed in patients. PTGDR could have a potential role as biomarker and pharmacogenetic factor in allergy. Pollens + mite allergy (at least) group includes patients with allergy to both pollens and mites regardless that they could have others sensitizations. The group pollens + mite allergy (only) includes patients who only have allergy to pollens and mites but not to any other group of aeroallergens.
